Physician profile
Ronald Johnson
NPI 1487759254
$1,626.70
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $260 · 2021: $462 · 2022: $533.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $650.17 | 2019-2022 | |
| Almirall LLC | $149.41 | 2021 | |
| Sun Pharmaceutical Industries INC. | $139.00 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $124.44 | 2019-2021 | |
| Janssen Biotech, INC. | $110.42 | 2019-2021 | |
| Incyte Corporation | $105.05 | 2022 | |
| Novartis Pharmaceuticals Corporation | $94.79 | 2019-2022 | |
| Pfizer INC. | $82.07 | 2019-2022 | |
| Lilly USA, LLC | $55.50 | 2020-2022 | |
| Ucb, INC. | $41.92 | 2021-2022 | |
| Galderma Laboratories, L.P. | $22.97 | 2019 | |
| Genzyme Corporation | $19.19 | 2021 | |
| Leo Pharma INC. | $19.17 | 2022 | |
| Dermira, INC. | $12.60 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.